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A novel α-conopeptide Eu1.6 
inhibits N-type (CaV2.2) calcium 
channels and exhibits potent 
analgesic activity
Zhuguo Liu1, Peter Bartels2, Mahsa Sadeghi2,3, Tianpeng Du4, Qing Dai1, Cui Zhu1, Shuo Yu1, 
Shuo Wang1, Mingxin Dong1, Ting Sun1, Jiabin Guo5, Shuangqing Peng5, Ling Jiang  4,  
David J. Adams  2,3 & Qiuyun Dai  1
We here describe a novel α-conopeptide, Eu1.6 from Conus eburneus, which exhibits strong anti-
nociceptive activity by an unexpected mechanism of action. Unlike other α-conopeptides that largely 
target nicotinic acetylcholine receptors (nAChRs), Eu1.6 displayed only weak inhibitory activity at the 
α3β4 and α7 nAChR subtypes and TTX-resistant sodium channels, and no activity at TTX-sensitive 
sodium channels in rat dorsal root ganglion (DRG) neurons, or opiate receptors, VR1, KCNQ1, L- and 
T-type calcium channels expressed in HEK293 cells. However, Eu1.6 inhibited high voltage-activated 
N-type calcium channel currents in isolated mouse DRG neurons which was independent of GABAB 
receptor activation. In HEK293 cells expressing CaV2.2 channels alone, Eu1.6 reversibly inhibited 
depolarization-activated Ba2+ currents in a voltage- and state-dependent manner. Inhibition of CaV2.2 
by Eu1.6 was concentration-dependent (IC50 ~1 nM). Significantly, systemic administration of Eu1.6 at 
doses of 2.5–5.0 μg/kg exhibited potent analgesic activities in rat partial sciatic nerve injury and chronic 
constriction injury pain models. Furthermore, Eu1.6 had no significant side-effect on spontaneous 
locomotor activity, cardiac and respiratory function, and drug dependence in mice. These findings 
suggest α-conopeptide Eu1.6 is a potent analgesic for the treatment of neuropathic and chronic pain 
and opens a novel option for future analgesic drug design.
The mere abundance of marine animals evolving large repertoires of neuroactive peptides underlies the sub-
stantial interest in the therapeutic potential that rests on natural products particularly from the venom of 
marine predatory fish-hunting cone snails (Conus species)1–3. More than 800 known Conus species have built 
a large genetic library with >200,000 neuroactive ligands of which less than 0.1% have been pharmacologically 
characterized4–6.
Many of these uncharacterized neuroactive peptides are currently under investigation for novel treatments 
in Parkinson’s disease, multiple sclerosis, lung cancer and intractable chronic pain conditions1,3,7. Omega 
(ω)-conotopeptide MVIIA (Prialt) from Conus magus was the first Conus peptide to be approved by U.S. and 
European regulatory agencies for the treatment of chronic intractable pain in patients who do not respond to con-
ventional opioid therapies8. However, the overall success of Prialt failed to be realized because of its neurological 
and cardiovascular side effects and its inconvenient method of application (intrathecal administration, I.T.)9–11. 
The smaller α-conopeptides (12–16 amino acids) of the A-superfamily exhibit a distinct pharmacological antag-
onism with respect to their high potency at inhibiting muscle or neuronal nAChRs12–16. Several α-conopeptides, 
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including Vc1.1, Rg1A, PeIA, and AuIB, have been reported to alleviate neuropathic pain by inhibiting N-type 
calcium channels via G protein-coupled GABAB receptor activation17–21.
The physiological role of N-type (CaV2.2) calcium channels in neuronal excitation and synaptic transmis-
sion has been well described and accentuates them as attractive targets for clinical pain intervention5–7,9,22–27. 
Voltage-gated calcium channels are comprised of a pore-forming α1B subunit which activates (open) upon mem-
brane depolarization to allow a brief and local Ca2+ influx into the cell, and then inactivates before returning to 
the resting state with membrane repolarization. This intrinsic and highly conserved mechanism is supported 
by one of the four known β subunits (β1 − β4) and a α2δ subunit (α2δ1 − α2δ4) which aid in a chaperone-like 
manner to modulate channel expression as well as biophysical and pharmacological channel properties28,29. The 
α1B and α2δ subunits have become of increasing interest as pharmacological targets to alleviate chronic pain 
conditions8,9,30,31.
In the present study, we describe a novel CaV2.2 inhibitor from the ivory cone snail (C. eburneus). Unlike other 
α-conopeptides that target neuronal nAChRs or GABAB receptors, Eu1.6 potently inhibits CaV2.2 with only a 
weak interaction at α3β4 and α7 nAChRs subtypes. Eu1.6 inhibited >30% of the high voltage-activated (HVA) 
calcium current in mouse DRG neurons and a detailed electrophysiological characterization of the inhibition of 
human CaV2.2 channels was carried out using a recombinant HEK293 cell expression system. Eu1.6 reversibly 
inhibited CaV2.2-mediated Ba2+ currents in a concentration-dependent manner and steady-state inactivation 
was enhanced at hyperpolarized membrane potentials. Most importantly, Eu1.6 exhibited analgesic activity in 
rat partial sciatic nerve injury (PNL) and chronic constriction injury (CCI) models at doses of 2.5–5.0 μg/kg, and 
was more potent than a combination of morphine (5 mg/kg) and gabapentin (100 mg/kg). To our knowledge, 
this is the first identified α-conopeptide to directly inhibit CaV2.2 channels and display potent analgesic activity.
Results
Cloning, synthesis and folding of Eu1.6. Classification of the conopeptide Eu1.6 was based on ER signal 
sequences of the precursors (gene superfamily) and Cys pattern of the mature peptide (Cys frameworks)32. As an 
initial strategy, peptide sequences were cloned from the venom glands of living cone snails of Conus eburneus har-
vested near Hainan in the South China Sea (Fig. 1a). A novel conopeptide precursor was cloned from C. eburneus 
by 3′ RACE using the conserved signal peptide sequence found in the A-superfamily conopeptides. The mature 
toxin sequence was predicted as GCCSNPACMLKNPNLC-NH2 with a cysteine pattern of CCX4CX7C (Fig. 1c), 
suggesting this peptide belongs to the α-4/7 family of conopeptides. In accord with conventional conopeptide 
nomenclature32, the cloned sequence that encodes the novel α-conopeptide was designated as Eu1.6. This cDNA 
sequence has been submitted to GenBank (accession number HQ446467).
The Eu1.6 linear peptide folded well and formed a major peak (Fig. 1b). The folded peptide was then puri-
fied by semi-preparative HPLC. The final synthesized Eu1.6 was further assessed using analytical reversed-phase 
HPLC, and its purity was greater than 98% with the expected molecular weight. HPLC results of one-step and 
two-step folding of the acetamidomethyl (Acm)-protected linear peptides are shown in Fig. 1b. The retention 
time of the synthesized Eu1.6 in the one-step folding was identical to that of Eu1.6, with a disulfide connectivity 
of I-III, II-IV forming in the two-step oxidation process Fig. 1b,d, indicating the disulfide bond connectivity of 
Eu1.6 was I-III, II-IV.
NMR solution structure of Eu1.6. The structural statistics for Eu1.6 are given in Supp. Table S1. The 
ensemble of the 20-lowest energy structures is shown in Fig. 2a and the ribbon representation is shown in Fig. 2b. 
The Eu1.6 peptide contains a short α–helix starting from Cys8 to Lys11. The rest of the peptide is stabilized by 
two disulfide bonds, Cys2-Cys8 and Cys3-Cys16. The loops are well defined and hydrogen bonds can be observed 
between Ser4 NH and Cys3 O, Cys8 NH and Asn5 O, Asn12 NH and Cys8 O, Cys16 NH and Asn12 O.
Eu1.6 exhibits potent analgesic activity in rat PNL and CCI models. Given that some 
α-conopeptides have been shown to exhibit analgesic activity, Eu1.6 was evaluated initially using a rat PNL 
model18,19. Eu1.6 displayed potent analgesic activity in this analgesic model whereby at 2 hr after ipsilateral mus-
cular injection (i.m.) of different doses of Eu1.6 (0.5 μg/kg (0.3 nmol/kg), 2.49 μg/kg (1.5 nmol/kg) and 24.9 μg/
kg (15 nmol/kg), the pain threshold was 170 ± 34.6 g, 197 ± 22.1 g, 169 ± 44.8 g (n = 8), respectively (Fig. 3a), 
higher than the starting value (125 ± 17.6 g, 147 ± 33.0 g, 107 ± 28.7 g; n = 8). The elevation percentage of rat 
pain threshold ((pain threshold − pain threshold of pre-experiment)/pain threshold of pre-experiment × 100%) 
at 2 hr after 24.9 μg/kg (15 nmol/kg) of Eu1.6 administration was 62% (Fig. 3b), similar to that observed for 
α-conotoxin Vc1.1 (27.1 μg/kg (15 nmol/kg), and morphine (5 mg/kg) with gabapentin (100 mg/kg) positive con-
trol group (62% and 50%, respectively). However, 4 hr after administration, the pain threshold elevation percent-
age decreased (49%, 24.9 μg/kg), but was still higher than Vc1.1 and the morphine plus gabapentin group (16% 
and 20%, respectively). Moreover, at 2 and 4 hr after the administration (i.v.) of different doses of Eu1.6 (1, 4.98, 
and 49.8 μg/kg), Eu1.6 still displayed potent analgesic activity with the pain threshold increasing to 151 ± 11.1 g, 
172 ± 43.8 g, 164 ± 36. and 139 ± 14.3 g, 152 ± 32.5 g, 153 ± 22.0 g (n = 8), respectively, from the starting values 
of 127 ± 13.8 g, 126 ± 20.5 g, 103 ± 9.5 g (n = 8) (Fig. 3c,d). The analgesic activity of Eu1.6 was further tested in 
the rat CCI pain model. The pain threshold significantly increased after the administration of different doses of 
Eu1.6 (Fig. 3e–h), and was similar to the results of PNL experiments. In the above PNL and CCI models, Eu1.6 
exhibited higher analgesic activity than Vc1.1 and the combination of morphine and gabapentin, and the effects 
were sustained for longer duration.
Eu1.6 inhibits nicotinic acetylcholine receptors (nAChR) with low potency. Given that Eu1.6 is 
an α-conopeptide, we tested Eu1.6 at various rat nAChR subtypes expressed in Xenopus oocytes. Eu1.6 (10 μM) 
inhibited the ACh-evoked current amplitude mediated by the rat neuronal α3β4 and α7 nAChR subtypes by 
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Figure 1. Cloning, synthesis and folding of α-conopeptide Eu1.6. (a) The cDNA sequence and predicted 
translation product of Eu1.6 (above). The signal peptide and mature toxin are shaded. The signal peptide is 
shown in gray, the propeptide is underlined, and the mature peptide is shown with white text on a blackground. 
HPLC analyses of the folded products of linear Eu1.6 and its Acm derivatives. Photograph of C. eburneus shell 
(right). (b) One-step oxidative folding of Eu1.6 (left). Traces from bottom to top: (a) linear peptide; (b) one-
step oxidized products; (c) purified product. Determination of the disulfide bond connectivity of Eu1.6 (right). 
Traces from bottom to top: (a) Linear peptide with Acm modification at Cys 2 and Cys 4; (b) the first oxidized 
product; (c) The second oxidized product and (d) Co-elution of the two-step folding products and one-step 
folding products. Samples were applied to a Calesil ODS-100 C18 column (4.6 mm × 250 mm) and eluted with a 
linear gradient of 0~1 min, 5–10% B (B is acetonitrile (0.1% TFA); 1~25 min, 10~50% B; 25~28 min, 50~95% B 
at a flow rate of 1 ml/min, 214 nm of wavelength. (c) Comparison of the primary structure of Eu1.6 with other 
α-conotoxins that act on nAChRs and GABAB receptor/CaV2.2.
Figure 2. NMR solution structure of Eu1.6. (a) Backbone ensemble of 20 lowest energy structures. The side 
chains of Cys residues are shown in red. (b) Ribbon representation of the closest-to-mean structure.
www.nature.com/scientificreports/
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30 ± 5% and 45 ± 2% (n = 4–6), respectively (Fig. 4). At the same concentration, Eu1.6 inhibited the α9α10 
nAChR subtype by only 11 ± 2% (n = 6) suggesting that the potent analgesic activity of Eu1.6 is unlikely to be due 
to the inhibition of α9α10 nAChRs.
Eu1.6 inhibits HVA calcium currents in rodent DRG neurons. A possible underlying mechanism of 
Eu1.6 action could involve the G protein-coupled GABAB receptor-mediated inhibition of HVA calcium chan-
nels33. The 4/7 α-conopeptide, Vc1.1, and 4/3 α-conopeptide, Rg1A, inhibition of N-type calcium channel cur-
rents via GABAB receptor activation was antagonized by the selective GABAB receptor antagonists CGP55845 
(1 µM) or phaclofen (50 µM). We tested 1 µM Eu1.6 in acutely dissociated mouse DRG neurons and observed 
inhibition of depolarization-activated Ca2+ channel current amplitude by 32.8 ± 4.9% (n = 8) in the absence 
and 32.1 ± 3.4% (n = 8) in the presence of CGP55845 (Fig. 5a,b). These results suggested that the inhibition of 
HVA calcium channels in DRG neurons by Eu1.6 was not mediated via GABAB receptor activation (Fig. 5d). 
Figure 3. Analgesic activity of Eu1.6 in rat PNL and CCI pain models. (a,b,e,f) PNL and CCI rats (n = 8/
group) were treated with sterile saline (i.m.), Eu1.6 (0.5, 2.49 and 24.9 μg/kg, i.m.), Vc1.1 (27.2 μg/kg, i.m.), or 
a combination of morphine (5 mg/kg), subcutaneous injection (sc) and gabapentin (100 mg/kg, intragastric 
administration (i.g.). Sham rats (n = 8) were treated with sterile saline (i.m.). (c,d,g,h) PNL and CCI rats (n = 8/
group) were treated with sterile saline (i.v.), Eu1.6 (1, 4.98 and 49.8 μg/kg, i.v.) or the combination of morphine 
(5 mg/kg, sc) and gabapentin (100 mg/kg, i.g.). The LHS graphs shows the mean pain threshold at pre-injection 
and 2, 4 and 6 h following treatments (a,c,e,g), whereas the RHS bar  graphs show the corresponding elevation 
percentage at 2 h and 4 h following treatments (b,d,f,h). The different groups were analyzed by one-way ANOVA 
followed by the LSD test for multiple comparison tests at a 0.05 level of significance. *p < 0.05 vs. saline, 
#p < 0.05 Eu1.6 (low dose group) vs. Vc1.1 or the combined group of morphine and gabapentin.
www.nature.com/scientificreports/
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To determine which of the various HVA calcium channels in mouse DRG neurons are inhibited by Eu1.6, 
ω-conotoxin CVIE (1 µM) was applied to selectively block N-type calcium channels. No further inhibition of 
HVA calcium channel currents by Eu1.6 was observed in the presence of CVIE (Fig. 5c) suggesting that the 
N-type calcium channel is the primary target of Eu1.6 (Fig. 5d). Eu1.6 (10 µM) was also tested on voltage-gated 
sodium channels in DRG neurons and shown that Eu1.6 inhibited TTX-sensitive (TTX-S) and TTX-resistant 
(TTX-R) Na+ currents by 5.5 ± 2.1% and 16.5 ± 4.2% (n = 4–6), respectively. These results show that 10 µM Eu1.6 
weakly inhibited TTX-R Na+ channels but was relatively inactive on TTX-S Na+ channels in rat DRG neurons 
(p < 0.05, t-test) (Supp. Fig. S4). Furthermore, Eu1.6 (1–10 µM) exhibited no activity at opioid receptors (Supp. 
Table S4), VR1 (vanilloid receptor subtype 1) or KCNQ1 channels expressed in HEK293 cells (Supp. Fig. S5c,d).
Eu1.6 reversibly inhibits human CaV2.2 channels expressed in HEK293 cells. To deter-
mine the mechanism of inhibition of HVA calcium channels by Eu1.6 observed in DRG neurons, we used 
HEK293 cells that stably expressed human CaV2.2 channels composed of the α1B subunit together with the β3 
and α2δ1 subunits. Whole-cell currents recorded using 10 mM Ba2+ as the charge carrier were inhibited in a 
concentration-dependent manner with an IC50 of 1.1 nM (n = 4) (Fig. 6a) confirming that Eu1.6 directly inhibits 
CaV2.2 channels. CaV2.2 inhibition by 1 µM Eu1.6 was reversible upon washout and could be repeated in the same 
experiment (Fig. 6b). Eu1.6 (1–5 µM) did not inhibit either L- or T-type calcium channels expressed in HEK293 
cells (n = 4–6) (Supp. Fig. S5a,b).
To investigate the effect of Eu1.6 inhibition on the CaV2.2 current-voltage (I-V) relationship, several con-
secutive I-V curves were recorded and the I-V relationship obtained in the absence (control) and presence of 
Eu1.6 (1 µM) is shown in Fig. 6(c,d). Depolarization-activated Ba2+ current amplitude was inhibited by >30% 
over a wide range of membrane potentials in the presence of 1 µM Eu1.6 (Fig. 6d). Half-maximal activation 
(V0.5) and slope of the conductance-voltage relationship were not significantly shifted in the presence of Eu1.6 
(V0.5 = 5.2 ± 1.9 mV, n = 14) compared with control (V0.5 = 8.7 ± 0.5 mV, n = 21) (p > 0.05, paired t-test, Supp. 
Table S2). The time to peak of the inward Ba2+ current fitted by a mono-exponential function (τact) was deter-
mined at 0 mV (Fig. 6e) and τact significantly increased from 2.7 ± 0.9 ms (control) to 7.4 ± 0.5 ms (n = 6) in the 
presence of 1 µM Eu1.6 (p < 0.05, paired t-test, Supp. Table S2). The CaV2.2 conductance-voltage (G-V) relation-
ship was determined by measuring the repolarizing tail current amplitude from test potentials to −50 mV for 
10 ms (Fig. 7a). The G-V curve was not significantly altered in the presence of Eu1.6 (Fig. 7b, Supp. Table S2), 
however, the peak current density was reduced by >40% in the presence of Eu1.6 (Fig. 7c) and time course of 
deactivation was significantly increased from 0.61 ± 0.12 ms to 1.75 ± 0.46 ms (n = 9; p < 0.05, paired t-test)) and 
reversible upon washout (Fig. 7d,e).
Figure 4. Eu1.6 inhibition of nicotinic acetylcholine receptor (nAChR) subtypes. Eu1.6 (10 µM) was applied by 
perfusion to oocytes expressing nAChRs as described in Methods. The error bars denote the S.E.M. of the data 
from four to six oocytes for each determination. (a) Representative ACh-evoked currents mediated by α9α10 
and α7 nAChRs in the absence (control) and presence of 10 µM Eu1.6. (b) Bar graph of the mean ACh-evoked 
current amplitude of nAChR subtypes in the presence of 10 μM  Eu1.6. Data are presented as Mean ± SEM, 
Statistical significance was determined with One-way ANOVA, *p < 0.05, **p < 0.001. (c) A summary of the 
effect of Eu1.6 on various neuronal nAChR subtypes.
www.nature.com/scientificreports/
6Scientific REPORTS |  (2018) 8:1004  | DOI:10.1038/s41598-017-18479-4
To determine if Eu1.6 affected CaV2.2 channel inactivation, the voltage-dependence of steady-state inactiva-
tion was investigated (Fig. 8a–c). CaV2.2 steady-state inactivation was shifted by −12 mV to more hyperpolarized 
potentials from V0.5inact of −54.7 ± 1.2 mV (control) to −66.8 ± 5.9 mV in the presence of Eu1.6 (n = 9; p < 0.05, 
unpaired t-test). Evaluation of Eu1.6 inhibition of CaV2.2 at −110 mV compared with −70 mV revealed enhanced 
steady-state inactivation by Eu1.6 at hyperpolarized holding potentials (Fig. 8c) indicating that Eu1.6 preferen-
tially inhibits the inactivated channel. This suggests that Eu1.6 is a potential novel state-dependent inhibitor of 
CaV2.2 channels.
Eu1.6 does not affect locomotor activity or the cardiovascular system. Conopeptides are known 
for their potential off-target effects due to systemic administration. To examine the possibility of any side effects 
of Eu1.6 on locomotion, activating or depressing effects of Eu1.6 on locomotor activity was tested by the rotarod 
test and spontaneous locomotor activity test. Furthermore, any potential effects of Eu1.6 on cardiac and respira-
tory function were assessed to evaluate the potential risk of a cardiac depressant effect. Globally, no physiological 
impairments of baseline parameters were observed with intramuscular injection of high doses (1–50 mg/kg) of 
Eu1.6 (Supp. Figs S1–S3).
Discussion
According to the number of the amino acids between cysteines (-CCXnCXmC-), α-conopeptides are divided 
into several subtypes, such as 3/5, 4/3, 4/4, 4/6, 4/7 and 5/5 subtypes12,34–36. Until now, 4/3 and 4/7 α-conopeptide 
subtypes, such as Rg1A, Vc1.1, and PeIA, have been shown to exhibit analgesic activities because they target 
both α9α10 nAChRs and GABAB receptors coupled to N-type calcium channels19–21. In contrast to the reported 
α- or αO-conopeptides37, Eu1.6 displayed only weak inhibitory activity at neuronal nAChR subtypes and did 
Figure 5. Eu1.6 inhibition of depolarization-activated Ba2+ currents is independent of GABAB receptor 
activation in mouse DRG neurons. (a) Superimposed representative time plots of IBa inhibition by 1 µM Eu1.6 in 
the presence of 1 µM CGP55845in mouse DRG neurons. Bars indicate the bath application of CGP55845, Eu1.6 
in the presence of CGP55845, and ω-conotoxin CVIE. Superimposed inward Ba2+ currents (bottom insets) 
obtained in the presence of 1 µM CGP 55845 (a), Eu1.6 in the presence of CGP 55845 (b), and 300 nM CVIE (c), 
are shown at the times indicated by lowercase letters. Dotted lines indicate zero-current level. (b) Time course of 
IBa inhibition by 1 µM Eu1.6 Eu1.6 in the presence of CGP55845 in mouse DRG neurons. Bars indicate the bath 
application of Eu1.6, Eu1.6 in the presence of CGP55845, and ω-conotoxin CVIE. Application of CGP 55845 did 
not antagonize the effect of Eu1.6 on HVA calcium channel. (c) Time course of the inhibition of IBa by 300 nM 
CVIE (b) and 1 µM Eu1.6 in the presence of 300 nM CVIE (c) in mouse DRG neurons. Inward IBa elicited by 
step depolarization applied at 0.1 Hz from a HP of −80 mV to −5 mV or 0 mV (as indicated in bottom inserts 
for each representative time course) plotted as a function of time. (d) Bar graph summary of inhibition of peak 
current amplitude by 1 µM Eu1.6, 1 µM Eu1.6 in the presence of 1 µM CGP55845, 300 nM CVIE, and 300 nM 
CVIE + 1 μM Eu1.6. Data are presented as Mean ± SEM. No significant difference was observed between 
inhibition of HVA calcium channel current by application of Eu1.6 and Eu1.6 + CGP55845 (P > 0.05, paired 
two-tailed t-test) and the inhibition of HVA calcium current by CVIE and CVIE + Eu1.6 (P > 0.05, paired two-
tailed t-test). Number of experiments is indicated in parentheses.
www.nature.com/scientificreports/
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not activate GABAB receptors to modulate N-type calcium channels. However, Eu1.6 did inhibit HVA, N-type 
calcium channel currents in isolated mouse DRG neurons whereby inhibition of HVA calcium channel currents 
by ω-conotoxin CVIE was not further inhibited by a maximally effective concentration of Eu1.6. This suggests 
that the Eu1.6 binding site(s) may overlap with that of ω-CVIE. Furthermore, Eu1.6 did not inhibit voltage-gated 
sodium channels in DRG neurons nor KCNQ1 channels or L- and T-type calcium channels expressed in HEK293 
cells (Supp. Figs S4–S5).
In HEK293 cells expressing CaV2.2 channels alone, Eu1.6 concentration-dependently inhibited 
depolarization-activated Ba2+ currents in a voltage- and state-dependent manner. Eu1.6 inhibition of human 
CaV2.2 is reminiscent of a partial inhibitor with a maximal effect of 40% at 1 µM. The voltage-dependence of 
activation did not appear to be largely affected, however, the time course of activation was increased by >2.7-fold. 
In contrast, steady-state inactivation exhibited a statistically significant shift of approximately −12 mV which 
is consistent with that observed for the I-V relationship. Partial block of Cav2.2 may be explained by either an 
allosteric effect of the conopeptide on the channel or due to partial steric block of the pore38. However, single 
channel studies investigating unitary currents and open channel probability in the presence of Eu1.6 will be 
required to determine the precise mechanism of action of Eu1.6 block of CaV2.2. To our knowledge, Eu1.6 is the 
first α-conotoxin reported to directly and reversibly inhibit N-type (CaV2.2) calcium channels.
Protein alignment revealed that Eu1.6 shares lower sequence identity among α-conopeptides except Vc1.2 
(75%). However, Vc1.2 potently inhibits α3β2, α7 and α9α10 nAChRs with IC50 values of 75 nM, 637 nM and 
1000 nM, respectively39. The difference between Eu1.6 and Vc1.2 at target is likely derived from residues in the 
second loop because their amino acid residues in the first loop are similar.
Eu1.6 exhibits significant analgesic activity in neuropathic pain (PNL and CCI) models at a low dose 
(5.0~25.0 μg/kg) and was higher than Vc1.1 and the combination of morphine (5 mg/kg, sc) and gabapentin 
(100 mg/kg, i.g.). The latter combination is effective in current neuropathic pain therapy40,41. Similar results were 
Figure 6. Eu1.6 concentration-dependent inhibition of human CaV2.2 expressed in HEK293 cells. (a) 
Concentration- response relationship obtained for Eu1.6 inhibition of CaV2.2 giving an IC50 of 1.1 nM and 
a maximum block of <50% (n = 4). (b) Ba2+current amplitude plotted as a function of time in the absence 
and presence of 1 µM Eu1.6 and 100 nM CVIE. Cells were activated by a depolarizing pulse from a holding 
potential of −80 mV to a test potential of +10 mv for 200 ms at 0.2 Hz, after reaching a plateau (max. block) cells 
were superfused (washout) with external bath solution for several minutes for complete recovery. (c) Voltage 
protocol used to determine the I-V relationship under control conditions and in the presence of 1 µM Eu1.6. 
Representative current traces recorded over a series of depolarizing testing potentials from a holding potential 
of −100 mV to −40 mV to +55 mV (∆5 mV increments) under control conditions and after >2 min. exposure 
to 1 µM Eu1.6 in the external bath solution. (d) I-V relationship recorded at certain time points in the absence 
(filled circle) and presence of Eu1.6 (open circle). (e) Activation kinetics (tau) measured in the absence (control, 
filled circle) and presence of 1 µM Eu1.6 (open circle) was determined by a mono-exponential function (inset) 
for a series of testing potentials derived from the same I-V traces.
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observed in the CCI model. Interestingly, Eu1.6 was also highly effective after i.v. administration in PNL and CCI 
rats. This is first α-conopeptide to show potent analgesic activity for neuropathic pain via intravenous adminis-
tration. Eu1.6 exhibits no apparent analgesic activity in sham rats, demonstrating its specificity for neuropathic 
pain. Importantly, at the high doses of 25 mg/kg (i.m.) and 100 mg/kg (i.v.), Eu1.6 did not exhibit any significant 
side-effects in acute tests of rats, and a more than 100-fold effective dose of Eu1.6 (5 mg/kg i.v.) had no significant 
effects on mice spontaneous locomotor activity (Fig. S2). Similarly, Eu1.6 doses of 166.3 μg/kg (i.m.) and 1 mg/kg 
(i.v.) did not show any significant effect on mice motor function, cardiac or respiratory function, demonstrating 
Eu1.6 has a high safety margin. In addition, Eu1.6 did not exhibit the morphine-like addictive symptoms after 
continuous administration of 24.90 µg/kg, 249 µg/kg, and 2490 µg/kg Eu1.6 for 8 days (Supp. Fig. S6).
In summary, we have characterized a novel α-conopeptide, Eu1.6, showing it to directly target N-type (Cav2.2) 
calcium channels with high potency in contrast to its activity at neuronal nAChRs subtypes. Eu1.6 exhibited 
potent analgesic activity in the rat PNL and CCI neuropathic pain models at μg/kg levels after intramuscular 
(i.m.) and intravenous (i.v.) administration. Importantly, Eu1.6 did not exhibit any significant side-effects for 
Figure 7. Eu1.6 slows deactivation kinetics of CaV2.2 channel. (a) Tail currents were determined at a 
repolarizing potential (−50 mV) for 10 ms in the absence (control) and presence of Eu1.6. Insert: expanded 
time scale of superimposed tail currents obtained in the absence (control, black line; washout, dashed line) 
and presence of Eu1.6 (grey line). (b) Conductance-voltage (G-V) relationships determined from tail currents 
recorded in the absence (control, filled circle) and presence of Eu1.6 (open circle). The current was normalized 
to its maximum current and fitted with a double Boltzmann function. (c) Current density plot was derived from 
the current amplitude (pA) divided by the cell capacitance (pF). See Supp. Tables S2 and S3 for parameter and 
significance testing. (d) Deactivation kinetics (tau) was determined by a mono-exponential fit of tail currents. 
The scatter plot depicts the deactivation kinetics in the absence (filled circle) and presence of Eu1.6 (open 
circle) for a series of experiments at a single prepulse potential. Statistical significance was determined with an 
unpaired t-test, *p < 0.05. (e) Representative deactivation kinetics of currents traces recorded in the absence 
(control, filled circle), after incubation (>2 min.) with Eu1.6 (open circle) and upon washout (open diamond).
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spontaneous locomotor activity, cardiac and respiratory function and drug dependence. These findings suggest 
Eu1.6 is potent analgesic for neuropathic pain and is a novel lead for further drug design associated with pain 
treatment.
Methods
Cloning of Eu1.6. Conus eburneus were harvested near Hainan Island in the South China Sea. The venom 
ducts were dissected from living cone snails and frozen immediately in liquid nitrogen. Total RNA was extracted 
and purified from ~100 mg of homogenized venom duct tissue using TRIZOL Reagent (Invitrogen, Carlsbad, CA, 
USA) as described previously42,43.
1 µg of total venom duct RNA was used to generate cDNA using M-MLV reverse transcriptase with a 3′-RACE 
adaptor, and the resulting cDNA used as the template for the first 3′RACE PCR reaction. To amplify the cDNA 
encoding the novel α-conopeptides, the following nested primers pairs were employed. Forward primers, outer 
primer F1 (5′-ATG GGC ATG CGG ATG ATG TTC-3′) and inner primer F2 (5′-CTG TTG GTT GTC TTG GCA 
ACC AC-3′), were designed based on the conserved sequence of the signal peptides of known A-superfamily 
conotoxins. Reverse 3′-RACE outer primer R1 (5′-TAC CGT CGT CGT TCC ACT AGT GAT TT-3) and reverse 
3′-RACE inner primer R2 (5′-CGC GGA TCC TCC ACT TGT GGT AGG G-3′), were provided in the 3′-Full 
RACE Core Set Ver.2.0 kit (TaKaRa Biotechnology, Dalian, China). Both the first and the second PCR amplifi-
cation reactions included an initial denaturation step carried out at 94 °C for 4 min, followed by 30 amplification 
cycles (94 °C for 30 s, 56 °C for 30 s and 72 °C for 1 min) and a final extension step at 72 °C for 10 min. PCR prod-
ucts were analyzed on a 1% agarose gel, the appropriate bands purified, ligated into pGEM-T Easy Vectors and 
transformed into E. coli. DH5α cells (TIANGEN Biotech Co., Ltd., Beijing, China). Clones containing the desired 
inserts were identified by PCR and subsequently sequenced.
Peptide synthesis, folding and disulfide connectivity analysis. The linear peptide Eu1.6 was syn-
thesized by the solid-phase method using an ABI 433 A peptide synthesizer as described previously44,45. The 
peptide-resin was cleaved in a reagent mixture composed of 8.8 ml TFA, 0.5 g DTT, 0.5 ml H2O and 0.2 ml tri-
isopropylsilane for 3 h at room temperature. The released peptide was filtered, precipitated with cold ether and 
folded in 0.1 M NH4HCO3 buffer (pH 8.2) at a concentration of 0.4 mg/ml for 24–48 h at room temperature. The 
folding procedure was monitored by HPLC. Following the oxidation step, the reaction was stopped by acidifica-
tion with acetic acid to a pH of 4.0–5.0. The mixture was then filtered and directly loaded on to a 25 × 250 mm 
preparative C18 column using a preparative HPLC pump (Waters Delta Prep 4000). The column was washed with 
buffer A (0.1% TFA in H2O) at a flow rate of 2.5 ml/min and then with buffer B (0.1% TFA in acetonitrile) at a 
Figure 8. Eu1.6 shifts the voltage-dependence of steady-state inactivation (SSI) of the CaV2.2 channel. The 
steady-state inactivation was determined by a triple pulse protocol. A long conditioning pulse over a series 
of membrane potentials (holding potentials), starting from −110 mV to 0 mV (10 mV increments, 10 s), was 
recorded immediately after a 50 ms prepulse to +10 mV (P1). Another brief pulse after the preconditioning 
pulse was recorded for 50 ms at +10 mV. (a) Representative current traces (P2) are shown in the absence and 
presence of 1 µM Eu1.6. Currents were normalized to the maximum current and plotted over a series of holding 
potentials. Data points were fitted with a single Boltzmann function as exemplified in (b). Insert: bar graph 
shows half-maximum inactivation (V0.5,inact) was shifted by more than 10 mV to more hyperpolarized potentials. 
(c) Bar graph of P2/P1 as a function of holding potential represents mean ± SEM values. Statistical significance 
for each holding potential was determined with an unpaired t-test, *p < 0.05, **p < 0.01 and ***p < 0.001.
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flow rate of 5 ml/min. The resulting peptide was further purified by semi-preparative RP-HPLC using a Kromasil 
10.0 × 250 mm C18 column. Confirmation of the correct molecular mass was ascertained by mass spectrometry 
on a ProFLEXTM-III MALDI-TOF spectrometer.
The disulfide arrangement of Eu1.6 synthesized by the one-step oxidative folding was determined by compar-
ison with peptide folding products of known disulfide connectivity as described previously44–46.
NMR spectroscopy. Eu1.6 was dissolved in 500 μl of 20 mM phosphate buffer (pH 5.5) containing 10% D2O. 
NMR experiments, including TOCSY, NOESY and DQF-COSY, were conducted on a Bruker Avance 800 MHz 
spectrometer using a TXI cryoprobe. All spectra were collected at 303 °K. The mixing times of TOCSY were 30 
and 70 ms, respectively. The mixing times used for NOESY experiments were 300, 400, 500 ms, respectively. H/D 
exchange experiment was performed at 303 °K by adding 500 μl D2O to the lyophilized sample.
Spectra were processed using NMRPipe software and peak analyses were conducted with the XEASY module 
in Cara (version 1.5.5)47. Spin systems were established by DQF-COSY and TOCSY spectra. NOE intensities 
in NOESY spectrum with a 500 ms mixing time were extracted by CARA 1.8.4.2 and converted into distance 
constraints. 3JHα-NH coupling constants were determined from DQF-COSY. A set of 100 structures was calcu-
lated using CYANA (version 2.1) with 239 non-redundant NOE and 8 dihedral angle constraints44. The final 20 
conformers with the lowest energies were refined using Amber11. Disulfide bonds were checked by measuring 
the inter-nuclear distances in structures calculated without disulfide bond constraints and then added to the 
final calculation. 70.8% of the phi-psi torsion angles in the structure were in the most favored regions in the 
Ramachandran plot. The three-dimensional structure was displayed using the MOLMOL graphics program. The 
data, including chemical shifts, were submitted to the BMRB database with access codes 21060 for Eu1.6.
Analgesic activity tests. Adult male Sprague-Dawley rats (SD, 220–250 g) (Beijing Animal Center, China) 
were housed in groups of eight and maintained on a 12 h light-dark cycle (light cycle from 8 am–8 pm) at a tem-
perature of 23 ± 2 °C and a relative humidity of 50%. Food pellets and water were available ad libitum. All meth-
ods and experimental protocols were approved and carried out in accordance with the guidelines and regulations 
of the Beijing Institutes for Biological Sciences Animal Research Advisory Committee and conformed to the 
European Community directives for the care and use of laboratory animals.
Rat partial sciatic nerve injury (PNL) and chronic constriction injury (CCI) pain models were used to deter-
mine the analgesic activity of Eu1.6. The model was established as described previously48,49. In sham-operated 
rats, the same surgery was performed, but the nerve was not ligated. Rats scoring below 80 g or over 160 g before 
operation were rejected (20%). For analgesia measures, mechanical pressure application was stopped at 160 g. 
All behavioral testing was performed seven days after surgery. Successful PNL and CCI models were defined as a 
30–50% decrease in mechanical paw withdrawal threshold (PWT) for the ipsilateral hind paw. PNL and CCI rats 
were subjected to mechanical stimulation using the paw pressure test to assess hyperalgesia-like responses in the 
hind paw ipsilateral to the ligated nerve. Nociceptive thresholds, expressed in grams, were measured with Ugo 
Basile analgesiometer (Ugo Basile, Italy) to produce increasing pressure to the hind paw until paw withdrawal 
occurred. The effects of drugs were systematically compared on the paw withdrawal to pressure. Paw withdrawal 
thresholds were measured at 2, 4 and 6 h following intramuscular (i.m.) and intravenous (i.v.) administration. 
Data are expressed as mean paw withdrawal threshold (g).
Seven days after surgery, successful rat models were randomly assigned to six groups that each received one 
of the following treatments: sterile saline (negative control), Vc1.1, a combination of morphine (5 mg/kg) and 
gabapentin (100 mg/kg) (positive control) or Eu1.6. Eu1.6 was dissolved in 0.9% sterile saline to a volume of 
200 μl and administered by intramuscular injection (0.5 μg/kg (0.3 nmol/kg), 2.49 μg/kg (1.5 nmol/kg) or 24.9 μg/
kg (15 nmol/kg) close to the injury site in the mid-thigh region or by intravenous injection (1 μg/kg (1 nmol/kg), 
4.98 μg/kg (3.0 nmol/kg) or 49.8 μg/kg (30 nmol/kg)). α-Conotoxin Vc1.1 was administered (27.2 μg/kg, 15 nmol/
kg) intramuscularly morphine by subcutaneous injection (sc) and gabapentin by intragastric administration (i.g.).
Two-electrode voltage clamp experiments in oocytes. Oocyte electrophysiology was carried out as 
described previously44,46. Rat nAChR subunits α2, α3, α4, α7, β2 and β4 were in pNKS2 vector, α9 in pGEMHE 
vector, α10 in pSGEM vector and human α7 in pMXT. Xenopus laevis oocytes were injected with 5 ng of cRNA, 
and then kept at 18 °C and maintained in sterile ND96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM 
MgCl2, and 5 mM HEPES, at pH 7.4) supplemented with 50 mg/l gentamycin and 100 μg/IU per milliliter peni-
cillin/streptomycin for 2–5 days before recording. All methods and experimental protocols were approved and 
carried out in accordance with the guidelines and regulations of the Beijing Institutes for Biological Sciences 
Animal Research Advisory Committee and  RMIT University, Melbourne, Australia. Membrane currents from 
Xenopus oocytes were recorded using a two-electrode voltage clamp setup (virtual ground circuit) with either an 
Axoclamp 900A or GeneClamp 500B amplifier (Molecular Devices, Sunnyvale, CA). All recordings were made 
at room temperature (21–23 °C) using a bath solution of ND96 as described above, and oocytes were voltage 
clamped at a holding potential of –80 mV. Voltage-recording and current-injecting electrodes were pulled from 
borosilicate glass (GC150T-7.5; Harvard Apparatus Ltd., Holliston, MA) and had resistances of 0.3–1.5 MΩ when 
filled with 3 M KCl. During recordings, the oocytes were perfused continuously at a rate of 2 ml/min including 
application of ACh (200 μM for α7 and 50 μM for all other nAChR subtypes) for 2 sec and 180–240 sec wash-
out periods between applications. No desensitization or run down of currents were observed between controls. 
Oocytes were incubated with the peptide for 300 sec before application of ACh plus peptide. Data were sampled 
at 500 Hz and filtered at 100 Hz. Peak ACh-evoked current amplitude was recorded using pClamp 10 software 
(Molecular Devices). The effects of peptide on ACh-evoked currents were defined as peak current amplitudes 
relative to the average peak current amplitude of 3–5 control ACh applications recorded before pre-incubation 
with the peptide. All electrophysiological data were presented as the mean  ± SEM of measurements taken from 
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4–6 oocytes for each nAChR subtype. Significance of inhibition was calculated by One-way ANOVA analysis 
compared to 0% inhibition (represented by value 1.0 in Fig. 4b) using GraphPad Prism (GraphPad Software Inc., 
La Jolla, CA).
Whole-cell electrophysiological recordings from rodent DRG neurons. The protocol of dorsal 
root ganglion (DRG) neuron preparation was approved and carried out in accordance with the University of 
Wollongong and RMIT University Animal Ethics Committees guidelines and regulations. Briefly, mice were euth-
anized with isoflurane inhalation following decapitation. DRG neurons were collected, digested, and mechani-
cally triturated from ganglia of 8–10 week-old C57BL/6 mice as described previously19. Cell suspensions were 
washed twice in supplemented DMEM (containing 10% heat-inactivated FBS and 1% penicillin/streptomycin) 
(Thermo Fisher Scientific), resuspended in supplemented DMEM and plated on poly-D-lysine/laminin-coated 
12 mm round coverslips (BD Biosciences, Bedford, MA, USA), incubated at 37 °C in high relative humidity 
(95%) and controlled CO2 level (5%), and used within 16–36 h. In rodent DRG neurons, membrane currents 
through HVA calcium channels were recorded in the whole-cell configuration of the patch clamp technique 
with an Axopatch 200B amplifier (Molecular Devices, LLC, Sunnyvale, CA) at room temperature (22–24 °C). 
Extracellular (bath) solution containing (in mM): 150 tetraethylammoonium (TEA)-Cl, 2 BaCl2, 10 D-glucose 
and 10 HEPES, pH 7.4. Fire-polished borosilicate (C150TF-7.5, Harvard Apparatus Ltd.) patch pipettes with 
tip resistance values of 1.5–2.2 MΩ were filled with an intracellular solution containing (in mM): 140 CsCl, 1 
MgCl2, 5 Mg-ATP, 0.1 Na-GTP, 5 1,2- bis(O-aminophenoxy)ethane-N,N,N′,N′ -tetraacetic acid tetracesium salt 
(BAPTA)-Cs4, and 10 HEPES-CsOH, pH 7.3. A voltage protocol using step depolarization from −80 mV to −5 
or 0 mv was used when examining HVA calcium channel current. Currents were generated by a computer using 
pCLAMP 10 software (Molecular Devices, LLC), filtered at 3 kHz and sampled at 10 kHz. Leak and capacitive 
currents were subtracted using a −P/4 pulse protocol.
Whole-cell calcium channel current recordings from HEK293 cells. Whole-cell Ba2+ currents of 
the N-type human isoform α1B (37b), β3 and α2δ1 were recorded from stable transfected HEK293 cells. External 
bath solution contained (in mM): 90 NaCl, 10 BaCl2, 30 TEA-Cl, 1 MgCl2, 5 CsCl, 10 D-glucose, 10 HEPES, pH 
adjusted to 7.3 with TEA-OH. Borosilicate fire polished pipettes (2–3 MΩ) were backfilled with internal solution 
containing (in mM): 120 K-gluconate, 2 MgCl2, 5 EGTA, 5 NaCl, 4 Mg-ATP, 10 HEPES, pH adjusted to 7.2 with 
CsOH. The series resistance (usually <8 MΩ) and the cell capacitance measured with the MultiClamp 700B 
Amplifier (Molecular Devices, LLC) and compensated by ~70% avoiding current oscillation. Ba2+ currents were 
sampled at 10 kHz and low pass-filtered at 1 kHz. Raw data acquisition was obtained with pClamp 10 and stored 
to a common CPU. Data analysis and curve fitting were performed by using GraphPad Prism software (San 
Diego, CA). The current-voltage (I-V) relationship was obtained from a holding potential (HP) of −100 mV and 
pulsed for 200 ms to a series of test potentials (TP) starting from −40 mV to +50 mV (Δ10 mV increments). 
The I-V relationship was fitted with the equation: IBa2+  = Gmax*(V − Erev)/(1 + exp ((V − V0.5)/k)) where Gmax is 
the maximum conductance: Erev is the reverse potential; V1/2 is the half-maximal activation potential and k is 
the slope. The steady-state inactivation was obtained from a HP of −100 mV stepping to a normalizing pulse of 
+10 mV for 50 ms followed by a series of 10 sec conditioning pulses from −110 mV to +10 mV and a 50 ms test 
pulse to +10 mV. Data were fitted with a Boltzmann equation: Irelative = Imin + (Imax − Imin)/(1 + exp ((V0.5 − V)/k) 
where Irelative is the normalized current; Imin and Imax are the current extremes and V0.5 is the half-maximal inacti-
vation. Activation kinetics was determined by tail currents where cells were depolarized by a 20 ms test pulse of 
an activating potentials starting from −50 mV to +100 mV. Tail currents were then measured after repolarization 
to −50 mV for 10 ms and normalized and fitted with a dual Boltzmann respectively, G/Gmax = Flow/(1 + exp ((V0.5 
low − V)/klow))/(1 Flow)/(1 − exp((V0.5 high − V)/khigh), with G as the tail current and Gmax as the peak tail current, 
Flow is the fraction of the low-threshold component;V0.5 low, V0.5 high, klow, and khigh are the half-activation poten-
tials and slope factors for the low and high threshold components and V0.5 act was determined when G = 0.5Gmax. 
Whole-cell currents were leak and capacity corrected with an online −P/4 protocol. Eu1.6 was dissolved in deion-
ized water and stored at stock solution of 10 mM. Cells were superfused by a gravity driven system. All experi-
ments were carried out at room temperature (21–23 °C).
Data analyses. The results of behavioural testing were expressed as mean ± SEM or SD and analyzed by 
separate one-way analysis of variance (ANOVA) followed by the Student–Newman–Keuls method for multiple 
comparison tests at the 0.05 level of significance.
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